Search results
Results from the WOW.Com Content Network
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
[65] [64] Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [66] [67] [68] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [66]
The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus, and increased liver enzymes in the blood due to liver damage. [5] [65] Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke, and 5 cases of muscle damage per 10,000 people treated. [34]
Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. [6]
These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
SAAM may affect people after long-term statin use even if they had no previous muscular side effects. [4] A differentiating feature between this and more benign statin side effects is SAAM typically has a late onset. While muscle pain (myalgia) is seen in 9-20% of patients treated with statins, it typically occurs in the first month of treatment.
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]